Introduction
Brucellosis is a major zoonotic disease worldwide caused by Brucella species, the infection is transmitted through consumption of unpasteurized milk and raw or undercooked meat from infected animals or by handling material and body fluids of these animals including inhalation of contaminated aerosols [1] , which makes it a potential agent for biological warfare purposes [2] . At risk professionals are shepherds and cattle breeders, tannery factories and slaughterhouses workers, veterinarians, butchers and microbiology laboratory technicians. Despite great progress in controlling the disease for most of the world, brucellosis is still considered endemic in certain regions such as South America, the Mediterranean Basin, Middle East and Arabian Peninsula [1] , and even in these regions it is often misdiagnosed, unrecognized and clearly underreported [1, 3] . The family Brucellaceae contains the genera Brucella, Crabtreella, Daeguia, Mycoplana, Ochrobactrum, Paenochrobactrum and Pseudochrobactrum. Brucella species are Gram-negative bacilli, facultative intracellular pathogens that can survive within phagocytic cells (), with variable degrees of virulence. In Portugal, the species most often implicated in human disease is Brucella melitensis [3] , capable of causing serious complications in any organ or system.
Contrarily to Brucella, Ochrobactrum spp rarely causes disease in humans; within the various species, O. anthropi seems to be the most clinically relevant. Due to being phenotypically and genetically closely related [4] several cases of misidentification have been reported [5] [6] [7] [8] [9] [10] . Ochrobactrum is considered an opportunistic and nosocomial pathogen and mostly associated with central venous catheters infections, especially in dialysis patients [11, 12] that lead to bacteremia and may cause localized infections such as endocarditis and osteomyelitis mainly in critically ill or immunocompromised patients [13, 14] . The misdiagnosis of brucellosis can delay the correct treatment, implying a longer course of the disease, risk of relapse and greater probability of sequelae and other complications. Furthermore, brucellosis poses an occupational hazard for any laboratory personnel working in a clinical microbiology laboratory and staff may be exposed to Brucella if an isolate is incorrectly identified and there is no clinical suspicion of brucellosis [9, 15] . night sweats and severe neck pain lasting for three weeks. She denied any other symptoms. The patient brought a magnetic resonance imaging (MRI) result that was previously requested by her family physician that showed evidence of cervical vertebral osteomyelitis (C4-C5). She had no relevant past medical history and took no medications. The patient worked as a shopping mall manager, lived in an apartment in the city and she had no contact with animals. She denied outdoor activities and had no history of recent travel abroad. Sporadically, she consumed fresh cheese. Her physical examination was unremarkable except for pain when mobilizing the cervical region. Laboratory testing showed only a slight elevation of the erythrocyte sedimentation rate (ESR). Two sets of blood cultures were obtained and the patient was admitted for further investigation.
Ochrobactrum anthropi was identified using the VITEK ® MS system in all of the four blood cultures collected at admission. The Antimicrobial Sensitivity Test (AST) showed susceptibility to imipenem, gentamicin, ciprofloxacin and trimethoprim/sulfamethoxazole, and resistance to amoxicillin and cefotaxime. Guided by the AST, antimicrobial treatment was initiated with ciprofloxacin. Despite antimicrobial therapy, there was no clinical improvement and the patient developed bicytopenia (anemia and leukopenia). An additional two sets of blood cultures were collected and on the 14th day of hospitalization, they were again identified as O. anthropi. Considering the poor clinical outcome with persistent positive blood cultures in a patient with no known underlying disease, added to the fact that the initial serological tests (Rose Bengal test and Wright agglutination) came back positive, and later through the detection of specific antibodies by enzyme-linked immunosorbent assay (ELISA) made a strong case for the possibility of misidentification. Samples were sent to Instituto Nacional de Saúde Doutor Ricardo Jorge (INSA) for genetic analysis. We decided to start antibacterial therapy for brucellosis with doxycycline, rifampin plus gentamicin, and the patient improved slowly but progressively. Despite evidence of efficacy in treating brucellosis with regimens containing ciprofloxacin, there is clinical and laboratorial evidence of its inferiority relative to regimens containing doxycycline [16, 17] due to its decreased activity in a low pH environment, which is the case with Brucella, as an intracellular organism capable of surviving within macrophage phagolysosomes [17] . The patient was discharged, back to her home, continuing antibacterial therapy and follow up at our outpatient clinic. The genetic analysis confirmed the presence of DNA from Brucella melitensis and the absence of DNA from O. anthropi. The patient maintained antibacterial therapy for four months. There was a re-evaluation with MRI after 6 months that showed slight attenuation of the previous enhancement of epidural and paravertebral soft tissues, suggesting a favorable response.
Discussion
Belonging to the same family, genus Brucella and Ochrobactrum share a large phylogenetic similarity but have important and significant differences in their ability to cause disease, mainly because of their interaction with the host cell [18] . Ochrobactrum is a saprophytic soil bacteria with a low virulence that does not replicate inside human cells or animals and only occasionally causes human disease [18, 19] . Brucella is an extremely effective pathogen with replication inside the cells and that can cause disease in a large number of animal species, including humans [20] . Another important difference lies in the structure of the cell membrane of these two bacteria, which confers intrinsic resistance of the genus Brucella to the polymyxins, something that does not happen with Ochrobactrum [4] and may help to differentiate between the two bacteria.
Regarding the initial antimicrobial therapy, ciprofloxacin is active against Brucella and can be used as an alternative in combination with other agents, mainly in non-localizing infections, but it shouldn't be used as a single agent due to its low efficacy and unacceptable high relapse rates [17, 21, 22] . Several cases of misidentification with Brucella and Ochrobactrum have been reported [5] [6] [7] [8] [9] [10] . These cases have led some laboratories to implement a safety measure with an automatic alert message whenever similar species to Brucella are identified, so that the laboratory staff may take the necessary safety precautions. In this case report, all blood cultures were initially identified as Ochrobactrum anthropi. However, because of the positive serology for Brucella, and the fact that an immunocompetent patient maintained persistent positive blood cultures for O. anthropi despite antimicrobial therapy, the possibility of misidentification was raised. Although mortality from brucellosis is low, a late diagnosis and treatment can be responsible for significant morbidity, with debilitating consequences. The risk of a wrong diagnosis is, therefore, of great clinical relevance.
Conclusions
Previous cases of misidentification have been described using several methods for rapid identification of microorganisms, namely by API ® 20NE system, misidentifying Brucella species as Moraxella phenylpyruvica [9, 10] and O. anthropi [7] ; by RapID ® NF plus as O. anthropi [5] ; by Baxter MicroScan ® panels as Haemophilus influenza biotype IV [10] and Moraxella species [10] and by MicroScan WalkAway ® system as Bergeyella zoohelcum [8] . In some of this cases, the samples were later evaluated and correctly identified using Vitek ® 2 system [5, 8] . More recently there was a case report with Vitek ® 2 system misidentifying Brucella suis as an O. anthropi [6] . To our knowledge, this is the first reported case of a misidentification of a Brucella species with O. anthropi, using a system based on MALDI-TOF technology (Vitek ® MS).
Despite the great breakthroughs in microbial identification and the wide use of fast and reliable commercial systems in some cases, correct identification remains challenging, furthermore this case demonstrates the difficulties of identifying Brucella species and the importance of clinical context for differential diagnosis. It also highlights the importance of not relying on a single identification method especially when the diagnosis is not firmly established. In the present case, there was also the risk of exposure for the laboratory personnel and timely identification may prevent laboratory-acquired infection.
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